Abstract 133P
Background
The use of CAR-T therapy for treating solid tumors has encountered challenges due to the structure and immunological properties of the tumors. However, microvesicles, which represent cell-free biosimilar drugs, offer a promising solution to overcome these obstacles. One of the main issues faced in this approach is the small yield of microvesicles from the cell sources. This challenge can be addressed by incorporating various induction methods such as ultrasonication.
Methods
T lymphocytes and anti-CD19 CAR-T cells were activated by CD3/CD28 abs for 24 h, then ultrasonication was used to obtain artificial vesicles (AVs) – T-AVs and CAR-T-AVs, respectively. AVs were isolated by differential centrifugation and analyzed with scanning electron microscopy (SEM) using Merlin (Carl Zeiss). Then the cytotoxic efficacy of AVs against PC3M and PC3M(CD19+) tumor cells was tested using xCelligence real-time cell analysis (RTCA) system.
Results
SEM data: CAR-T-AVs (n=263) were predominantly smaller in size than T-AVs (n=376). The major population was represented by 51-75 nm particles with a narrow monodisperse peak. Whereas for T-AVs, most particles the size distribution was much wider, in the range of 75-200 nm. RTCA data: for PC3M control, neither added T/CAR-T cells nor their respective AVs had any significant effect on tumor cell proliferation. Opposite to that, for the PC3M(CD19+) tumor line, the cell index began to decrease 30 hrs after CAR-T-AVs addition – interestingly, with more pronounced effect in the wells with a lower concentration of vesicles (10 μg/ml). Both T-AVs and CAR-T-AVs showed a less pronounced cytotoxic effect at higher concentration (35 μg/ml), potentially due to nonspecific toxicity.
Conclusions
Ranging particles size distribution may indicate diverse dynamics in the cell membrane and intracellular content in response to activation of T/CAR-T cells and treatment with ultrasonic. Doze-dependence of CAR-T-AVs cytotoxicity and their detailed mechanism of action shall be addressed in the future studies. The work was funded by the Russian Science Foundation grant 23-24-00224 and performed in accordance with the Strategic Academic Leadership Program of the Kazan (Volga Region) Federal University (PRIORITET-2030).
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The work was funded by the Russian Science Foundation grant 23-24-00224 and performed in accordance with the Strategic Academic Leadership Program of the Kazan (Volga Region) Federal University (PRIORITET-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
93P - A new platform for fast-track molecular stratification of endometrial carcinomas enabling timely treatment decisions in precision oncology
Presenter: Susanne Walz
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract